- Home
- GDL vs COYA Comparison
GDL vs COYA Comparison
Compare GDL & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDL | COYA |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 102.7M |
| IPO Year | 2006 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GDL | COYA |
|---|---|---|
| Price | $8.37 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.21 |
| AVG Volume (30 Days) | 12.8K | ★ 145.8K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $387.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $8.01 | $3.71 |
| 52 Week High | $8.67 | $7.75 |
Technical Indicators
Market Signals| Indicator | GDL | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 51.27 |
| Support Level | $8.34 | $4.42 |
| Resistance Level | $8.52 | $5.17 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 53.56 | 47.75 |
Price Performance
Historical ComparisonAbout GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.